Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12)

Padmaja K Rani1, Rajiv Raman1, Aditi Gupta1, Swakshyar S Pal1, Vaitheeswaran Kulothungan2 and Tarun Sharma1*

Abstract

Background: The concordance of microalbuminuria and diabetic retinopathy (DR) has been well reported in persons with type 1 diabetes; however, for type 2 diabetes, there is paucity of data especially from population-based studies. The aim of this study was to estimate the prevalence of albuminuria (micro- and macroalbuminuria) among persons with type 2 diabetes and determine its role as a risk factor for presence and severity of DR.

Methods: A population-based cross sectional study was conducted in cohort of 1414 subjects with type 2 diabetes from Chennai metropolis. All the subjects underwent comprehensive eye examination including 45 degrees four-field stereoscopic digital photography. DR was clinically graded using Early Treatment Diabetic Retinopathy Study scales. A morning urine sample was tested for albuminuria. Subjects were considered to have microalbuminuria, if the urinary albumin excretion was between 30 and 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours. The statistical software used was SPSS for Windows, Chicago, IL. Student t-test for comparing continuous variables, and \( \chi^2 \) test, to compare proportions amongst groups were used.

Results: The prevalence of microalbuminuria in the study subjects was 15.9% (226/1414), and that of macroalbuminuria, 2.7% (38/1414). Individuals with macroalbuminuria in comparison to micro- or normoalbuminuria showed a greater prevalence of DR (60.5% vs. 31.0% vs. 14.1%, \( p < 0.001 \)), and also a greater severity of the disease (60.9% vs. 21.4 vs. 9.9, \( p < 0.001 \)).

Conclusions: Every 6th individual in the population of type 2 diabetes is likely to have albuminuria. Subjects with microalbuminuria were around 2 times as likely to have DR as those without microalbuminuria, and this risk became almost 6 times in the presence of macroalbuminuria.

Keywords: Diabetic Retinopathy, Microalbuminuria, Macroalbuminuria, Risk factor, Type 2 Diabetes
men and between 11.9 and 71% in women. DR is responsible for 4.8% of the 37 million cases of blindness throughout the world [5]. The concordance of microalbuminuria and DR has been well reported in persons with type 1 diabetes [6-8]; however, for type 2 diabetes, there is paucity of data especially from population-based studies regarding the association of microalbuminuria with DR [9-14]. The present population based study was carried out to estimate the prevalence of albuminuria (micro- and macro-) in type 2 diabetes mellitus and report its influence as a risk factor for the presence and severity of DR.

Materials and methods
Study subjects were recruited from the Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS), which was a population-based cross sectional study. The study design and research methodology of SN-DREAMS 1 is described in detail elsewhere [15]. The study area was Chennai metropolis with a population of 4.3 million, distributed in 155 divisions of ten zones.

A computed sample size of 5830 individuals was estimated assuming the prevalence of DR in the general population to be 1.3%, with a relative precision of 25%, a drop-out rate of 20%, and a design effect of 2. Inclusion criteria included Individuals aged 40 years or above or turning 40 in the current year and residing for a minimum of six months at the same residence. Individuals residing for a period of less than six months at the same residence, temporary residents (whose permanent residence is elsewhere), a resident who dies after the enumeration but prior to examination, and those who cannot be contacted after five attempts by the social worker at their residence were excluded from the study.

Thus, 5999 subjects from the general population aged >40 years were enumerated. To ensure that data is collected from all socioeconomic groups, multistage random sampling was stratified, on the basis of economic criteria. To avoid patient selection bias, sampling was done in two stages: selection of divisions and selection of study subjects. Selection of divisions was done using computer generated random numbers; ensuring that one division per one corporate zone is represented in the sample. Eligible study subjects were then randomly selected from each division.

Of the 5999 subjects enumerated, 1414 persons identified with diabetes (both known and newly diagnosed) were analyzed for the study (96.20% response rate for first fasting blood sugar estimation, 85.60% response rate for base hospital examination, 8.7% turned out as non diabetic after second blood sugar and 0.78% of retinal images were un-gradable). Subjects with type 2 diabetes were identified based on the American Diabetes Association criteria [16]. Persons with known diabetes were previously diagnosed cases of diabetes whether or not they were using either oral anti-glycemic drugs or insulin or both. Persons with newly-diagnosed diabetes were those who had their fasting blood glucose level ≥110 mg/dl on two separate days. The study was approved by the Institutional Review Board, and written informed consent was obtained from subjects as per the Helsinki declaration. In order to ensure that the diagnostic measurements of glucose were quality assured, many quality control measures were taken. A comprehensive instruction manual and a start-up training session helped to standardize all the examination and diagnostic procedures. The glucometer was calibrated every day and its reproducibility was assessed by measuring the blood glucose for the same patient six times and also with two machines. The collected data was scrutinized manually before its entry into the computer. The measurements were centralized at the base hospital.

Albuminuria estimation was done by a semi-quantitative procedure (Bayer Clinitek 50 Urine Chemistry Analyzer) with the first morning urine sample [17]. The Clinitek Microalbumin strip contains two reagent areas that test for albumin and creatinine in urine and provide semiquantitative results. In this study, only the albumin results were used. The albumin test is based on dye binding, using a high-affinity sulfonephthalein dye. At a constant pH, the development of any blue color is due to the presence of albumin. The resulting strip color ranges from pale green to aqua blue. The results were read with the use of the Clinitek 50 Urine Chemistry Analyzer (Bayer Health- Care, Elkhart, Ind., USA). Sensitivity and specificity for microalbuminuria diagnosis have been reported to be 100 and 81% for Clinitek Microalbumin [18]. The diagnostic performance of measuring UAC in a spot morning urine sample in predicting microalbuminuria in subsequent 24-hour urine collections has been reported to be satisfactory, and, moreover, comparable to that of measuring ACR [19]. Subjects were considered to have microalbuminuria, if the Urinary Albumin Excretion (UAE) was between 30 and 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours [20]. Glycosylated hemoglobin (HbA1c) fractions were estimated by using Merck Micro Lab 120 semi-automated analyzer (Bio-Rad DiaSTAT HbA1c Reagent Kit) [16]. Severity of DR was clinically graded using Early Treatment Diabetic Retinopathy Study scales [21]. Retinal photographs were taken after pupillary dilatation (Carl Zeiss Fundus Camera, Visucamilit, and Jena, Germany); all patients underwent 45° and 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours [20]. Glycosylated hemoglobin (HbA1c) fractions were estimated by using Merck Micro Lab 120 semi-automated analyzer (Bio-Rad DiaSTAT HbA1c Reagent Kit) [16]. Severity of DR was clinically graded using Early Treatment Diabetic Retinopathy Study scales [21]. Retinal photographs were taken after pupillary dilatation (Carl Zeiss Fundus Camera, Visucamilit, and Jena, Germany); all patients underwent 45° and 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours, and macroalbuminuria at more than 300 mg/24 hours [20]. Glycosylated hemoglobin (HbA1c) fractions were estimated by using Merck Micro Lab 120 semi-automated analyzer (Bio-Rad DiaSTAT HbA1c Reagent Kit) [16]. Severity of DR was clinically graded using Early Treatment Diabetic Retinopathy Study scales [21]. Retinal photographs were taken after pupillary dilatation (Carl Zeiss Fundus Camera, Visucamilit, and Jena, Germany); all patients underwent 45° four-field stereoscopic digital photography. For those who showed evidence of any DR, additional 30° seven-field stereo digital pairs were taken. All photographs
were graded by two independent observers in a masked fashion; the grading agreement was good (k = 0.83). When the evaluation of the two independent observers of DR did not agree, a third observer was referred to.

Statistical analyses were performed using the statistical software (SPSS for Windows, ver.13.0 SPSS Science, Chicago, IL). The results were expressed as mean ± SD if the variables were continuous, and as percentage, if categorical. Student t-test for comparing continuous variables, and χ² test, to compare proportions amongst groups were used. Individuals with newly-diagnosed diabetes were given a value of zero for duration of diabetes. P value of ≤0.05 was considered as significant. Both univariate and multivariate logistic regression analyses were performed to study the effect of various risk factors using microalbuminuria and macroalbuminuria as dependent variables. From the univariate analysis, variables with p values ≤0.05 and those, which were already established as risk factors, were included in the multivariate logistic regression analysis to derive at the parsimonious model. These variables included age, duration of diabetes, body mass index, systolic and diastolic blood pressure, and HbA1c.

**Results**
Table 1 provides the definitions of the terms used in the study.

Table 2 shows the prevalence of micro- and macroalbuminuria in the study population. Out of 1414 subjects, 1166 were known cases of diabetes and 248 were having newly-diagnosed diabetes. Overall, the prevalence of microalbuminuria in the study subjects was 226 out of 1414, 15.9% (95% CI: 13.9-17.8), and that of macroalbuminuria was 38 out of 1414, 2.7% (95% CI: 1.8-3.5). The prevalence of microalbuminuria was 191 out of 1166, 16.4% in individuals with known diabetes, and 35 out of 248, 14.1%, in those with newly diagnosed diabetes (p = 0.38). However, the prevalence of macroalbuminuria showed statistically significant differences between these 2 groups (3.1% vs. 0.8%, p = 0.04).

Table 3 summarizes the clinical characteristics among the study population with regard to normo-, micro- and macroalbuminuria. The mean age of the total study population (n = 1414) was 56.3 ± 10 yrs; 750 (53.04%) were men. Several clinical parameters showed highest value in individuals with macroalbuminuria followed by micro- and normoalbuminuria. These parameters included age, duration of diabetes and systolic blood pressure (p < 0.001). The body mass index (BMI) (Kg/m²) was the lowest in individuals with macroalbuminuria compared to micro- and normoalbuminuria (23.5 ± 3.8 vs. 24.9 ± 4.5 vs. 25.5 ± 3.9, p = 004). The diastolic blood pressures were higher in those individuals with macro- or microalbuminuria compared to those with normal albuminuria (83.8 ± 12.9 vs. 84.0 ± 11.5 vs. 81.5 ± 11.2, p = 005), and so was true for HbA1c (9.0 ± 2.3 vs. 9.0 ± 2.3 vs. 8.0 ± 2.1, p < 0.001). Individuals with macroalbuminuria in comparison to micro- or normoalbuminuria showed a greater prevalence of DR (60.5% vs. 31.0% vs. 14.1%, p < 0.001), and also a greater severity of the disease (60.9% vs. 21.4 vs. 9.9, p < 0.001). There was no significant association between serum lipids and albuminuria (p = 0.299 for total cholesterol, p = 0.119 for HDL and p = 0.896 for triglycerides).

Results of regression analysis of risk factors related to albuminuria are shown in Table 4. For microalbuminuria, the significant variables included increase in age per year Odds Ratio (OR) 1.01 (95% CI: 1.00-1.04), increase in systolic blood pressure per mm of Hg OR 1.02 (95% CI: 1.00-1.02), increase in HbA1c per gm% OR 1.18 (95% CI: 1.11-1.26), presence of DR OR 2.10 (95% CI: 1.46-3.01) and sight-threatening DR OR 2.49 (95% CI: 1.15-5.37). For macroalbuminuria, significant variables included increase in systolic blood pressure per mm of Hg OR 1.02 (95% CI: 1.00-1.04), presence of DR OR 6.50 (95% CI: 3.11-13.61), and sight-threatening DR OR 14.19 (95% CI: 5.31-37.96). Decreased BMI was associated with macroalbuminuria OR 0.89 (95% CI: 0.80-0.98).

### Table 1 Definitions used in the Study

| Sno | Variable | Definition |
|-----|----------|------------|
| 1   | Albuminuria | The patient was considered to have normoalbuminuria, if Urinary Albumin Excretion (UAE) was < 30 mg/24 hour, microalbuminuria, if UAE was 30-300 mg/24 hours, and macroalbuminuria if UAE was >300 mg/24 hours |
| 2   | Diabetes Mellitus | Persons with known diabetes were those who were using either oral anti-glycemic drugs or insulin or both. Persons with newly-diagnosed diabetes were those who had their fasting blood glucose level ≥110 mg/dl on two separate days. |
| 3   | Non-sight-threatening Diabetic Retinopathy | Non-sight-threatening diabetic retinopathy included cases of mild or moderate non-proliferative diabetic retinopathy |
| 4   | Sight-threatening Diabetic Retinopathy | Sight-threatening diabetic retinopathy (Referable diabetic retinopathy) was defined as severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy and clinically significant macular edema |
Discussion

The present study primarily reports the prevalence of albuminuria (micro- and macro-) amongst persons with type 2 diabetes and evaluates its role as a risk factor for presence and severity of DR. Besides, it also reports the risk factors related to albuminuria as its secondary outcome measures.

In the present study, the age- and gender adjusted prevalence of diabetes mellitus in a population older than 40 years was 28.2%. Other studies have also shown a similar high prevalence of diabetes mellitus from India [22-24].

The National Urban Diabetes Study (2000) [25] showed the prevalence of diabetes in a population older than 40 years to be 23.8% in 6 cities in India including Chennai, and more recently, the Chennai Urban Rural Epidemiology Study (2003-2004) estimated the prevalence in those older than 40 years to be 30.1% [26].

In the present study, individuals with type 2 diabetes showed prevalence of microalbuminuria to be around 16%, and that of macroalbuminuria, around 3%. It means that every 6th individual in the population of individuals with diabetes had albuminuria. While occurrence of microalbuminuria was observed in equal proportions in individuals with known diabetes vs. newly diagnosed (16.4% vs. 14/1%), macroalbuminuria was more common in the former group (3.1% vs. 0.8%). The prevalence of micro- and macroalbuminuria was reported to be around 27% and 5% by Unnikrishnan et al [2]. Like the results of our study, they also noted that individuals with known diabetes had higher prevalence of macroalbuminuria than those with newly diagnosed diabetes (6.5% vs 3.9%); no differences were noted with regard to microalbuminuria.

Our study highlighted that subjects with microalbuminuria were around 2 times as likely to have DR as those without microalbuminuria, and this risk became almost 6 times in the presence of macroalbuminuria. A similar trend was noted for sight-threatening DR, the odds were 2.5 times for microalbuminuria and 14 times for macroalbuminuria. The DCCT in type 1 diabetes mellitus reported that there is a relationship between DR and diabetic nephropathy [27]. Within the study group that showed evidence of minimal DR at baseline, 10% had elevated UAE rates. For the population with type 2 diabetes, though the association between advanced degrees of DR and macroalbuminuria (or proteinuria) is well-known [5,13,14,28,29], the relationship with lower levels of UAE within the range of microalbuminuria is controversial. Some investigators have reported a positive association [5,28,30-33, while in other studies this has not been observed [11,34-36]. Boelter et al [33] also

### Table 2 Prevalence of Albuminuria in the Study Population

| Groups          | Overall (N = 1414) n (%) (95% CI) | KD* (N = 1166) n (%) (95% CI) | NDD† (N = 248) n (%) (95% CI) | p for KD vs NDD |
|-----------------|-----------------------------------|--------------------------------|-----------------------------|-----------------|
| Normoalbuminuria| 1150 (81.3%) (79.3 - 83.3)        | 939 (80.5%) (78.2- 82.8)      | 211 (85.1%) (80.5-9.5)      | 0.095           |
| Microalbuminuria| 226 (15.9%) (13.9-17.8)          | 191 (16.4%) (4.2 - 8.5)       | 35 (14.1%) (9.7-18.4)       | 0.376           |
| Macroalbuminuria| 38 (2.7%) (1.8-3.5)              | 36 (3.1%) (2.1- 4.0)          | 2 (0.8%) (-0.3-1.9)        | 0.044           |

* KD, Persons with known diabetes; † NDD, Persons with newly diagnosed diabetes

### Table 3 Clinical Characteristics of the Study Subjects

| Variables* | Normoalbuminuria n = 1414 | Microalbuminuria n = 1166 | Macroalbuminuria n = 248 | p |
|------------|---------------------------|---------------------------|--------------------------|----|
| Male       | 609 (53.0)                | 118 (52.2)                | 23 (60.5)                | 0.631 |
| Age (years)| 55.7 ± 10.0               | 58.6 ± 9.6                | 596 ± 9.67               | < 0.001 |
| Duration of DM (years) | 5.2 ± 6.1              | 6.6 ± 6.6                | 8.9 ± 6.2                | < 0.001 |
| BMI (kg/m2) | 25.5 ± 3.9              | 24.9 ± 4.5                | 23.5 ± 3.8               | 0.004 |
| SBP (mm of Hg) | 137.4 ± 199.9           | 145.6 ± 22.8              | 150.4 ± 23.0             | < 0.001 |
| DBP (mm of Hg) | 81.5 ± 11.2             | 840 ± 11.5                | 838 ± 12.9               | 0.005 |
| HbA1c (gm %) | 8.0 ± 2.1               | 9.0 ± 2.3                | 9.0 ± 2.3               | < 0.001 |
| Serum TC   | 186.1 ± 40.4             | 1868 ± 39.3              | 1965 ± 569               | 0.299 |
| Serum HDL  | 39.2 ± 10.2              | 388 ± 9.3                | 425 ± 13.2               | 0.119 |
| Serum TGL  | 153.4 ± 104.4           | 1561 ± 80.4              | 1489 ± 75.2              | 0.896 |
| Presence of DR | 162 (14.1)           | 70 (31.0)                | 23 (60.5)               | < 0.001 |
| Presence of Sight threatening DR | 16 (9.9)          | 15 (21.4)                | 14 (60.9)              | < 0.001 |

Abbreviations: DM, Diabetes Mellitus; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HbA1c, Glycosylated Hemoglobin; DR, Diabetic Retinopathy

* Data are means ± SD or n (%)
reported the presence of renal involvement, including urinary albumin excretion within the microalbuminuria range in type 2 diabetic patients with proliferative diabetic retinopathy. They emphasized that all patients with proliferative diabetic retinopathy should undergo an evaluation of renal function including urinary albumin measurements. A few studies have identified that the renal changes seen in individuals with both microalbuminuria and retinopathy had a distinct pattern compared to those having microalbuminuria without retinopathy. Severe retinopathy has been described as more closely associated with glomerulosclerosis, with Kimmelstiel-Wilson nodules, than with mesangial sclerosis [37].

Logistic regression analysis identified increasing age, raised blood pressure, and poor glycemic control as influencing microalbuminuria. Though a very subtle connection has been reported between urinary albumin, DR and lipids [38], we did not find a significant association between serum lipids and albuminuria in our study. BMI was inversely related to macroalbuminuria, however, this finding may only reflect the worst nutritional state of patients with more advanced renal disease and not a causal relationship. A poor nutritional status has been reported among subjects with diabetic nephropathy due to many factors, including higher resting energy expenditure, increased muscle protein breakdown [as reported in patients with type 2 DM undergoing hemodialysis] and, in some cases, restrictive dietary advice [39]. Raised blood pressure also influenced macroalbuminuria. The EURODIAB study in type 1 diabetes mellitus showed that the correlation between increasing blood pressure and albumin excretion rate was only confirmed in patients who also had DR, independently of glycemic control or diabetes duration, suggesting that DR, in association with increased blood pressure, is an important independent risk factor for diabetic nephropathy progression [40]. Unnikrishnan et al [2] reported association of systolic blood pressure with both micro- and macroalbuminuric groups and diastolic blood pressure with only microalbuminuric group. Poor glycemic control as a risk factor for microalbuminuria was reported in various studies [2,5,7]. Good glycemic and hypertension control should be recommended to prevent the occurrence of these complications of diabetes.

The association between microalbuminuria and DR observed in the present study could be explained by the view that microalbuminuria might represent a state of generalized vascular dysfunction [41]. Enzymes involved in the metabolism of anionic components of the extracellular matrix (e.g. heparan sulphate proteoglycan) vulnerable to hyperglycaemia, seem to constitute the primary cause of albuminuria and its associated complications. Genetic polymorphism of such enzymes [41], as well as of several candidate genes [42-47] has been hypothesized to be the main reason for the variation in susceptibility.

Alternatively, microalbuminuria and DR may share common risk factors. The duration of diabetes and blood pressure levels are well-known risk factors for both DR and diabetic nephropathy [48,49]. There are other factors which damage vessels in both retina and kidney. For example, Klein et al [50] showed that microalbuminuria could be seen in 29.2% of insulin taking patients and 22% of non-insulin dependent patients. Likewise, Kim et al [51] reported that fasting plasma level of insulin and systolic blood pressure has independent correlation with microalbuminuria. Besides common mechanisms, renal damage may accelerate retinopathy which is associated with serum levels of fibrinogen and lipoproteins [52]. Also, albuminuria has been considered as a predictor of DR and coronary heart disease [53].

There are potential shortcomings in our study that require comment. A major limitation was the use of single urine sample for estimation of microalbuminuria for
Micro- or macroalbuminuria are more likely to have DR as those without albuminuria.

Acknowledgements
We acknowledge the support RD Tata Trust, Mumbai, for this project.

Author details
1Shri Bhagwan Mahavir Vitreoretinal Services, 18, College Road, Sankara Nethralaya, Chennai-600 006, Tamil Nadu, India. 2Department of Preventive Ophthalmology (Epidemiology and Biostatistics), 18, College Road, Sankara Nethralaya, Chennai-600 006, Tamil Nadu, India.

Authors’ contributions
PKR and RR participated in acquisition of data and drafting the manuscript. AG and SSP participated in analysis and writing the manuscript. VK performed the statistical analysis. TS participated in study design and gave final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 16 January 2011 Accepted: 25 May 2011
Published: 25 May 2011

References
1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Unnikrishnan RI, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R, Mohan V: Prevalence and risk factors of diabetic nephropathy in an urban Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care 2007, 30:2019-2024.
3. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. The World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetes Drifting Group. Diabetologia 1985, 28(Suppl):615-640.
4. Sobngwi E, Mbanya JC, Moukouri EN, Nku KB: Microalbuminuria and retinopathy in a diabetic population of Cameroon. Diabetes Res Clin Pract 1999, 44:191-196.
5. Wirta O, Pasternack A, Mustonen J, Laippala P, Lähde Y: Retinopathy is independently related to microalbuminuria in type 2 diabetes mellitus. Clin Nephrol 1999, 51:29-34.
6. WHO-Magnitude and causes of Visual impairment. 2010 [http://www.who.int/mediacentre/factsheets/fs282/en/].
7. Loveastam-Adrian M, Agardh E, Agardh CD: The temporal development of retinopathy and nephropathy in type 1 diabetes mellitus during 15 years diabetes duration. Diabetes Res Clin Pract 1999, 45:15-23.
8. Marshall SM, Alberti KG: Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes. Q J Med 1989, 70:61-71.
9. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993, 16:996-1003.
10. Retnakaran R, Cull CA, Thorne KJ, Adler AI, Holman RR, UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetic Study 74. Diabetes 2006, 55:1832-1839.
11. Voutilainen-Kaunisto RM, Teraivaara ME, Uusitupa MI, Niskanen LK: Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects 10-year follow-up from the diagnosis. J Diab Comp 2001, 15:24-33.
12. Olivaras NdF, Andreassen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study “Diabetes Care in General Practice”, Denmark. Diabetologia 1993, 36:1007-1016.
13. Looker HC, Krakoff J, Knowler WC, Bennett PH, Klein R, Hanson RL: Longitudinal studies of incidence and progression of diabetic
retnopathy assessed by retinal photography in Pima Indians. Diabetes Care 2003, 26:320-326.
14. Savage S, Estacio RO, Jeffers B, Schrier RW: Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996, 19:1245-1248.
15. Aggarwal S, Ramam R, Paul PG, Rani PK, Uthra S, Gayathree R, McCarty C, Kumaramanickavel G, Sharma T: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS 1): study design and research methodology. Ophthalmol Epimediol 2005, 12:143-153.
16. Goldstein DE, Little RR, Lorenze RA, Maloney II, Nathan OM, Peterson CM, American Diabetes Association: Tests of glycaemia in diabetes. Diabetes Care 2003, 26(Suppl 1):106-108.
17. Le Floch JP, Mane M, Rodier M, Passa P: Interest of Clinitek Microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients. Diabetes Metabol 2001, 27:36-39.
18. Gansevoort RT, Verhac JR, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE, for the PREVEND Study Group: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005, 94: S28-35.
19. Sarafidis PA, Rehle J, Bogojvlic Z, Basta E, Chugh A, Bakris GL: A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol 2008, 29:324-329.
20. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parking HH, Steffes MW, American Diabetes Association: Nephropathy in Diabeties. Diabetes Care 2004, 27(Suppl 1):79-83.
21. Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE, Davis MD: An alternative method of grading diabetic retinopathy. Ophthalmology 1988, 93:1163-1175.
22. Raman Kutty V, Joseph A, Soman CR: High prevalence of type 2 diabetes in an urban settlement in Kerala, India. Ethn Health 1999, 4:231-239.
23. Gupta A, Gupta R, Sarm M, Rastogi S, Gupta VP, Kothari K: Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Prat 2003, 61:69-76.
24. Zargar AH, Khan AK, Masoodi SR, Laway BA, Wani AI, Barchi MI, Dar FA: Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in the Kashmir Valley of the Indian subcontinent. Diabetes Res Clin Prat 2000, 47:135-146.
25. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasanna Kumar NA, Nair JD, Diabetes Epidemigology Study Group in India (DES): High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001, 44:1094-1101.
26. Mohan V, Deepa M, Deepa R, Santhirisingh C, Fanoos S, Ganesan A, Datta M: Secular trends in the prevalence of diabetes and glucose tolerance in urban South India—the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia 2006, 49:1175-1179.
27. Molitch ME, Steffes MW, Cleary PA, Nathan DM: Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group (corrected). Kidney Int 1993, 43:688-674.
28. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997, 314:783-788.
29. Phokhunthorn T, Thatnarong D: Retinopathy and macro-albuminuria in type 2 diabetic patients. J Med Assoc Thai 2003, 96:804-809.
30. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU: Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 1998, 21:530-534.
31. Singh SK, Behere A, Singh MK: Diabetic retinopathy and microalbuminuria in lean type 2 diabetes mellitus. J Assoc Physicians India 2001, 49:439-441.
32. Durruty P, Carpentier C, Krause P, Garcia de los R: Evaluation of retinal involvement in type 2 diabetes with microalbuminuria. Rev Med Chil 2000, 128:1085-1092.
33. Boehner MC, Gross JL, Canani LH, Costa LA, Lisboa HR, Três GS, Lavinsky J, Azevedo MC: Proliferative diabetic retinopathy is associated with microalbuminuria in patients with type 2 diabetes. Braz J Med Biol Res 2006, 39:1033-1039.
34. Cignarelli M, De Cesco ML, Damato A, Gennari M, Pagliarini S, Santoro S, Cardia L, De Parse G, Giorgi R: High systolic blood pressure increases prevalence and severity of retinopathy in NIDDM patients. Diabetes Care 1992, 15:1002-1008.
35. Cruickshanks KJ, Ritter LL, Klein R, Moss SE: The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993, 100:862-867.
36. Potisat S, Surisut A, Kraintichai U, Jongsareeja T: The relationship between microalbuminuria by using urine dipsticks and diabetic retinopathy in type 2 diabetes. J Med Assoc Thai 2008, 91:846-851.
37. Swartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D: Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998, 13:2547-2552.
38. Olivaurs ND, Nielsen NV, Andersen AH: Diabetic retinopathy in newly diagnosed middle-aged and elderly diabetic patients. Prevalence and interrelationship with microalbuminuria and triglycerides. Grovett's Arch Clin Exp Ophthalmol 2001, 239:664-672.
39. Raffatin C, Lasseur C, Paupe P, Barthe N, Combe C, Rigalleau V: Nutritional status in patients with diabetes and chronic kidney disease: a prospective study. Am J Clin Nutr 2007, 85:96-101.
40. Stephenson JM, Fuller JH, Vickers AK, Avkai R: Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Diabetologia 1995, 38:599-603.
41. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32:219-226.
42. Levy AP, Roquin A, Hochberg J, Herer P, Marsh S, Nakhol FM, Skorecki K: Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 2000, 343:969-70.
43. Nakhol FM, Zoabi R, Kanter Y, Zoabi M, Skorecki K, Hochberg I, Liehu R, Miller B, Levy AP: Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001, 44:602-604.
44. Aishe R, Levy AP: In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1:19-28.
45. Nomiyama T, Tanaka Y, Piao L, Nagasaka K, Sakai K, Oghara T, Nakajima K, Watada H, Kawamori R: The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet 2003, 48:139-141.
46. Li L, Xiang K, Zheng T, Zhan C: Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem 2003, 254:335-338.
47. Moooyaart AL, Valk EU, van Es LA, Bijn JA, de Heer E, Freedman BI, Dekkers OM, Baelde HJ: Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 2011, 54:344-353.
48. Stratton IM, Kohner EM, Ackroyd S, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001, 44:156-163.
49. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Caillot CA, Wright AD, Deebek OM, Enevoldsen A, IDDM Complications Study. Diabetologia 2001, 44:358-359.
50. Klein R, Klein BE, Moss SE: Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 1993, 16:1325-1330.
51. Kim CH, Kim HK, Park HS, Hong SK, Park SW, Lee KU: Association of microalbuminuria and atherosclerotic risk factors in non-diabetic subjects in Korea. Diabetes Res Clin Prat 1998, 40:191-199.
52. Manavat MR, Afakami M, Shoji MR: Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 2004, 4:9.
53. Lunetta M, Infantone L, Calogero A, Infantone E: Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Prat 1998, 40:45-51.
54. Olivarius ND, Siemsma V, Nielsen AB, Hansen LJ, Rosenvinge L, Mogensen CE: Predictors of mortality of patients newly diagnosed with clinical type 2 diabetes: a 5-year follow up study. BMC.Endocr.Disord 2010, 10:14.
55. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007, 24:137-144.

56. Glassock RJ Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010, 12:364-368.

57. Solbu MD, Jenssen TG, Eriksen BO, Toft I. Changes in insulin sensitivity, renal function and markers of endothelial dysfunction in hypertension—the impact of microalbuminuria: a 13 year follow-up study. Metabolism 2009, 58:408-415.

58. Silva AM, Schaan BD, Signori LU, Plentz RD, Moreno H Jr, Bertoluci MC, Irgoyen MC. Microalbuminuria is associated with impaired arterial and venous endothelial dependent vasodilation in patients with type 2 diabetes. J Endocrinol Invest 2010, 33:696-700.

59. Foster MC, Keyes MJ, Larson MG, Vita JA, Mitchell GF, Meigs JB, Vasan RS, Benjamin EJ, Fox CS. Relations of measures of endothelial function and kidney disease: the Framingham Heart Study. Am J Kidney Dis 2008, 52:859-867.

60. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.

doi:10.1186/1758-5996-3-9

Cite this article as: Rani et al. Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12). Diabetology & Metabolic Syndrome 2011 3:9.